Tag Archives: Valeant Pharmaceuticals Intl Inc

Mizuho Securities Still Bearish on Valeant Pharmaceuticals Intl Inc (VRX)

Analyst Irina Koffler from Mizuho Securities reiterates her Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) with a price target of $11, marking a 52% decline from current levels. The analyst notes that she “wants to get more constructive” when

RBC Analyst Remains Neutral on Valeant Pharmaceuticals Intl Inc (VRX)

RBC Capital analyst, Douglas Miehm, weighed in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) following a review of Derm NRx and ophth NRx prescriptions. The analyst believes that prescriptions have remained relatively flat, with Derm NRx up only 0.9% week-over-week and ophth NRx down 0.5%

John Paulson 4Q Picks: Shire PLC (ADR) (SHPG), Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical Industries Ltd (ADR) (VRX)

New York based hedge fund, Paulson & Co revised its portfolio after a harsh year with a 24.09% loss. The hedge fund, which currently has a portfolio value of $16.73B, made a few notable additions since the beginning of the

Deutsche Bank Provides an Update on Valeant Pharmaceuticals Intl Inc (VRX)

Although analyst Gregg Gilbert of Deutsche Bank currently has a suspended rating on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), he was compelled to review the company in a note yesterday, in which he outlined what a “new model” for the embattled pharmaceutical company